Figures & data
Table I. Summary of study characteristics.
Table II. Summary of mutation data and outcome measures.
Figure 1. The association between KRAS mutations in exons 3 and 4 with the a) ORR, b) PFS and c) OS in patients with KRAS exon 2 wild-type mCRC treated with anti-EGFR monoclonal antibodies. control, wild-type; events, response; experimental, mutant type; HR, hazard ratio; OR, odds ratio, seTE, standard error of HR; TE, Ln(HR).
![Figure 1. The association between KRAS mutations in exons 3 and 4 with the a) ORR, b) PFS and c) OS in patients with KRAS exon 2 wild-type mCRC treated with anti-EGFR monoclonal antibodies. control, wild-type; events, response; experimental, mutant type; HR, hazard ratio; OR, odds ratio, seTE, standard error of HR; TE, Ln(HR).](/cms/asset/fa5efe96-ec19-4f97-85a4-8205713b0682/ionc_a_895036_f0001_b.gif)
Figure 2. The association of NRAS mutations with the a) ORR, b) PFS and c) OS of patients with KRAS wild-type mCRC treated with anti-EGFR monoclonal antibodies. control, wild-type; events, response; experimental, mutant type; HR, hazard ratio; OR, odds ratio, seTE, standard error of HR; TE, Ln(HR).
![Figure 2. The association of NRAS mutations with the a) ORR, b) PFS and c) OS of patients with KRAS wild-type mCRC treated with anti-EGFR monoclonal antibodies. control, wild-type; events, response; experimental, mutant type; HR, hazard ratio; OR, odds ratio, seTE, standard error of HR; TE, Ln(HR).](/cms/asset/c4dfc75a-6327-48a5-9b92-5b1cbb31cf76/ionc_a_895036_f0002_b.gif)
Figure 3. The associations of BRAF mutations with the a) ORR, b) PFS and c) OS of patients with KRAS wild-type mCRC treated with anti-EGFR monoclonal antibodies. control, wild-type; events, response; experimental, mutant type; HR, hazard ratio; OR, odds ratio, seTE, standard error of HR; TE, Ln(HR).
![Figure 3. The associations of BRAF mutations with the a) ORR, b) PFS and c) OS of patients with KRAS wild-type mCRC treated with anti-EGFR monoclonal antibodies. control, wild-type; events, response; experimental, mutant type; HR, hazard ratio; OR, odds ratio, seTE, standard error of HR; TE, Ln(HR).](/cms/asset/849625f6-0e79-4328-a5c1-6df2296eebd4/ionc_a_895036_f0003_b.gif)
Figure 4. The associations of PIK3CA mutations with the a) ORR, b) PFS and c) OS of patients with KRAS wild-type mCRC treated with anti-EGFR monoclonal antibodies. control, wild-type; events, response; experimental, mutant type; HR, hazard ratio; OR, odds ratio, seTE, standard error of HR; TE, Ln(HR).
![Figure 4. The associations of PIK3CA mutations with the a) ORR, b) PFS and c) OS of patients with KRAS wild-type mCRC treated with anti-EGFR monoclonal antibodies. control, wild-type; events, response; experimental, mutant type; HR, hazard ratio; OR, odds ratio, seTE, standard error of HR; TE, Ln(HR).](/cms/asset/21b16011-68fd-442f-9a83-b2f72d39963a/ionc_a_895036_f0004_b.gif)
Figure 5. The associations of PTEN alterations with the a) ORR, b) PFS and c) OS of patients with KRAS wild-type mCRC treated with anti-EGFR monoclonal antibodies. control, wild-type; events, response; experimental, mutant type; HR, hazard ratio; OR, odds ratio, seTE, standard error of HR; TE, Ln(HR).
![Figure 5. The associations of PTEN alterations with the a) ORR, b) PFS and c) OS of patients with KRAS wild-type mCRC treated with anti-EGFR monoclonal antibodies. control, wild-type; events, response; experimental, mutant type; HR, hazard ratio; OR, odds ratio, seTE, standard error of HR; TE, Ln(HR).](/cms/asset/37e71c6e-acde-4e04-bacf-00c1b1a902c7/ionc_a_895036_f0005_b.gif)
Table III. Response rates in metastatic colorectal cancer to anti-EGFR treatment.